Latest stories on CMND
Clearmind Medicine Successfully Completes Part A of its FDA Regulated Phase I/II Trial | CMND Stock News
StockTitan67 · bullishproduct/pr
Clearmind Medicine Reports Positive Retention Results for Intranasal Formulation of its Psychedelic-Based Neuroplastogen MEAI
Business Insider63 · neutralproduct/pr
Clearmind Shares Promising Real-World Insights from Ongoing CMND-100 First-in-Human Trial | CMND Stock News
StockTitan67 · bullishproduct/pr
Clearmind Medicine Advances Its Innovation with Newly Granted U.S. Patent, Enhancing Global Patent Strength | CMND Stock News
StockTitan63 · neutralproduct/pr
Clearmind Medicine Reaches Major Milestone, Completing Part A Treatment in FDA‑Regulated Phase I/II Trial | CMND Stock News
StockTitan63 · neutralproduct/pr
Clearmind Medicine Granted U.S. Patent for Binge Behavior Regulators | CMND Stock News
StockTitan63 · neutralproduct/pr
Clearmind Medicine Completes Dosing for Part A of its of FDA-Regulated Phase I/II Clinical Trial | CMND Stock News
StockTitan63 · neutralproduct/pr
Clearmind Medicine to Feature New Insights from CMND-100 Psychedelic Clinical Trial on “Inside MEAI” Webinar | CMND Stock News
StockTitan56 · neutralproduct/pr
Clearmind Medicine Expands Patent Footprint in Japan to Target Depression Market
MarketChameleon63 · neutralproduct/pr
Clearmind Medicine Expands Patent Portfolio With Japanese Filing for Non-Hallucinogenic Depression Therapy
MarketChameleon63 · neutralproduct/pr
Clearmind Medicine to implement 1-for-10 reverse share split
Seeking Alpha25 · bearishgeneral